Longitudinal effects of the SSRI paroxetine on salivary cortisol in Major Depressive Disorder

Henricus G. Ruhe; Sharina J. Khoenkhoen; Koen W. Ottenhof; Maarten W. Koeter; Roel J. T. Mocking; Aart H. Schene

doi:10.1016/j.psyneuen.2014.10.024

Longitudinal effects of the SSRI paroxetine on salivary cortisol in Major Depressive Disorder

Henricus G. Ruhe^*, Sharina J. Khoenkhoen, Koen W. Ottenhof, Maarten W. Koeter, Roel J. T. Mocking, Aart H. Schene

^*Corresponding author for this work

Interdisciplinary Centre Psychopathology and Emotion regulation (ICPE)

Research output: Contribution to journal › Article › Academic › peer-review

41 Citations (Scopus)

268 Downloads (Pure)

Abstract

Hypothalamic-pituitary-adrenal (HPA)-axis dysregulation is a prominent finding in more severe Major Depressive Disorder (MDD), and is characterized by increased baseline cortisol levels at awakening (BCL), blunted cortisol awakening response (CAR) and increased area under the cortisol curve (AUC). Selective serotonin reuptake inhibitors (SSRIs) appear to normalize HPA-axis dysfunction, but this is hardly investigated longitudinally.

We studied salivary BCL, CAR and AUC at awakening and 30 min thereafter. We compared measurements in initially drug-free MDD-patients with healthy controls (HCs) at study-entry. In patients, we repeated measures after 6 and 12 weeks' treatment with the SSRI paroxetine. Non-responding patients received a randomized dose-escalation after six weeks' treatment.

We found no significant study-entry differences in BLC, CAR or AUC between MDD-patients (n = 70) and controls (n = 51). In MDD-patients, we found general decreases of BCL and AUC during paroxetine treatment (p

Original language	English
Pages (from-to)	261-271
Number of pages	11
Journal	Psychoneuroendocrinology
Volume	52
DOIs	https://doi.org/10.1016/j.psyneuen.2014.10.024
Publication status	Published - Feb-2015

Keywords

SSRI
Depressive disorder
HPA-axis
Cortisol
Treatment response
Remission
PITUITARY-ADRENAL AXIS
AWAKENING RESPONSE
PROPENSITY SCORE
DOSE-ESCALATION
STATE VARIATION
HPA AXIS
ANTIDEPRESSANT
CITALOPRAM
WAKING
GLUCOCORTICOIDS

Access to Document

10.1016/j.psyneuen.2014.10.024

Longitudinal effects of the SSRI paroxetine on salivary cortisolFinal publisher's version, 1.09 MBLicence: Elsevier

Handle.net

Persistent link

Cite this

@article{0c9a721f8fe44f7aa63d8b79722cc4ea,

title = "Longitudinal effects of the SSRI paroxetine on salivary cortisol in Major Depressive Disorder",

abstract = "Hypothalamic-pituitary-adrenal (HPA)-axis dysregulation is a prominent finding in more severe Major Depressive Disorder (MDD), and is characterized by increased baseline cortisol levels at awakening (BCL), blunted cortisol awakening response (CAR) and increased area under the cortisol curve (AUC). Selective serotonin reuptake inhibitors (SSRIs) appear to normalize HPA-axis dysfunction, but this is hardly investigated longitudinally.We studied salivary BCL, CAR and AUC at awakening and 30 min thereafter. We compared measurements in initially drug-free MDD-patients with healthy controls (HCs) at study-entry. In patients, we repeated measures after 6 and 12 weeks' treatment with the SSRI paroxetine. Non-responding patients received a randomized dose-escalation after six weeks' treatment.We found no significant study-entry differences in BLC, CAR or AUC between MDD-patients (n = 70) and controls (n = 51). In MDD-patients, we found general decreases of BCL and AUC during paroxetine treatment (p",

keywords = "SSRI, Depressive disorder, HPA-axis, Cortisol, Treatment response, Remission, PITUITARY-ADRENAL AXIS, AWAKENING RESPONSE, PROPENSITY SCORE, DOSE-ESCALATION, STATE VARIATION, HPA AXIS, ANTIDEPRESSANT, CITALOPRAM, WAKING, GLUCOCORTICOIDS",

author = "Ruhe, {Henricus G.} and Khoenkhoen, {Sharina J.} and Ottenhof, {Koen W.} and Koeter, {Maarten W.} and Mocking, {Roel J. T.} and Schene, {Aart H.}",

year = "2015",

month = feb,

doi = "10.1016/j.psyneuen.2014.10.024",

language = "English",

volume = "52",

pages = "261--271",

journal = "Psychoneuroendocrinology",

issn = "0306-4530",

publisher = "PERGAMON-ELSEVIER SCIENCE LTD",

}

TY - JOUR

T1 - Longitudinal effects of the SSRI paroxetine on salivary cortisol in Major Depressive Disorder

AU - Ruhe, Henricus G.

AU - Khoenkhoen, Sharina J.

AU - Ottenhof, Koen W.

AU - Koeter, Maarten W.

AU - Mocking, Roel J. T.

AU - Schene, Aart H.

PY - 2015/2

Y1 - 2015/2

N2 - Hypothalamic-pituitary-adrenal (HPA)-axis dysregulation is a prominent finding in more severe Major Depressive Disorder (MDD), and is characterized by increased baseline cortisol levels at awakening (BCL), blunted cortisol awakening response (CAR) and increased area under the cortisol curve (AUC). Selective serotonin reuptake inhibitors (SSRIs) appear to normalize HPA-axis dysfunction, but this is hardly investigated longitudinally.We studied salivary BCL, CAR and AUC at awakening and 30 min thereafter. We compared measurements in initially drug-free MDD-patients with healthy controls (HCs) at study-entry. In patients, we repeated measures after 6 and 12 weeks' treatment with the SSRI paroxetine. Non-responding patients received a randomized dose-escalation after six weeks' treatment.We found no significant study-entry differences in BLC, CAR or AUC between MDD-patients (n = 70) and controls (n = 51). In MDD-patients, we found general decreases of BCL and AUC during paroxetine treatment (p

AB - Hypothalamic-pituitary-adrenal (HPA)-axis dysregulation is a prominent finding in more severe Major Depressive Disorder (MDD), and is characterized by increased baseline cortisol levels at awakening (BCL), blunted cortisol awakening response (CAR) and increased area under the cortisol curve (AUC). Selective serotonin reuptake inhibitors (SSRIs) appear to normalize HPA-axis dysfunction, but this is hardly investigated longitudinally.We studied salivary BCL, CAR and AUC at awakening and 30 min thereafter. We compared measurements in initially drug-free MDD-patients with healthy controls (HCs) at study-entry. In patients, we repeated measures after 6 and 12 weeks' treatment with the SSRI paroxetine. Non-responding patients received a randomized dose-escalation after six weeks' treatment.We found no significant study-entry differences in BLC, CAR or AUC between MDD-patients (n = 70) and controls (n = 51). In MDD-patients, we found general decreases of BCL and AUC during paroxetine treatment (p

KW - SSRI

KW - Depressive disorder

KW - HPA-axis

KW - Cortisol

KW - Treatment response

KW - Remission

KW - PITUITARY-ADRENAL AXIS

KW - AWAKENING RESPONSE

KW - PROPENSITY SCORE

KW - DOSE-ESCALATION

KW - STATE VARIATION

KW - HPA AXIS

KW - ANTIDEPRESSANT

KW - CITALOPRAM

KW - WAKING

KW - GLUCOCORTICOIDS

U2 - 10.1016/j.psyneuen.2014.10.024

DO - 10.1016/j.psyneuen.2014.10.024

M3 - Article

SN - 0306-4530

VL - 52

SP - 261

EP - 271

JO - Psychoneuroendocrinology

JF - Psychoneuroendocrinology

ER -

Longitudinal effects of the SSRI paroxetine on salivary cortisol in Major Depressive Disorder

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this